Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Genetic Approaches to Facilitate Antibacterial Drug Development.

Literature DB >> 25680982

Genetic Approaches to Facilitate Antibacterial Drug Development.

Abstract

Very few chemically novel agents have been approved for antibacterial chemotherapies during the last 50 yr. Yet new antibacterial drugs are needed to reduce the impact on global health of an increasing number of drug-resistant infections, including highly drug-resistant forms of tuberculosis. This review discusses how genetic approaches can be used to study the mechanism of action of whole-cell screening hits and facilitate target-driven strategies for antimicrobial drug development.

Entities: Disease

Mesh：

Substances：
Antitubercular Agents

Year: 2015 PMID： 25680982 PMCID： PMC4484962 DOI： 10.1101/cshperspect.a021139

Source DB: PubMed Journal: Cold Spring Harb Perspect Med ISSN： 2157-1422 Impact factor: 6.915

121 in total

Review 1. Structure-based druggability assessment--identifying suitable targets for small molecule therapeutics.

Authors: Eric B Fauman; Brajesh K Rai; Enoch S Huang
Journal: Curr Opin Chem Biol Date: 2011-06-23 Impact factor: 8.822

2. Mechanism-based inactivation by aromatization of the transaminase BioA involved in biotin biosynthesis in Mycobaterium tuberculosis.

Authors: Ce Shi; Todd W Geders; Sae Woong Park; Daniel J Wilson; Helena I Boshoff; Orishadipe Abayomi; Clifton E Barry; Dirk Schnappinger; Barry C Finzel; Courtney C Aldrich
Journal: J Am Chem Soc Date: 2011-10-24 Impact factor: 15.419

3. Bisubstrate adenylation inhibitors of biotin protein ligase from Mycobacterium tuberculosis.

Authors: Benjamin P Duckworth; Todd W Geders; Divya Tiwari; Helena I Boshoff; Paul A Sibbald; Clifton E Barry; Dirk Schnappinger; Barry C Finzel; Courtney C Aldrich
Journal: Chem Biol Date: 2011-11-23

4. Genomic profiling of drug sensitivities via induced haploinsufficiency.

Authors: G Giaever; D D Shoemaker; T W Jones; H Liang; E A Winzeler; A Astromoff; R W Davis
Journal: Nat Genet Date: 1999-03 Impact factor: 38.330

5. Use of a tetracycline-inducible system for conditional expression in Mycobacterium tuberculosis and Mycobacterium smegmatis.

Authors: Paul Carroll; D G Niranjala Muttucumaru; Tanya Parish
Journal: Appl Environ Microbiol Date: 2005-06 Impact factor: 4.792

6. Platensimycin is a selective FabF inhibitor with potent antibiotic properties.

Authors: Jun Wang; Stephen M Soisson; Katherine Young; Wesley Shoop; Srinivas Kodali; Andrew Galgoci; Ronald Painter; Gopalakrishnan Parthasarathy; Yui S Tang; Richard Cummings; Sookhee Ha; Karen Dorso; Mary Motyl; Hiranthi Jayasuriya; John Ondeyka; Kithsiri Herath; Chaowei Zhang; Lorraine Hernandez; John Allocco; Angela Basilio; José R Tormo; Olga Genilloud; Francisca Vicente; Fernando Pelaez; Lawrence Colwell; Sang Ho Lee; Bruce Michael; Thomas Felcetto; Charles Gill; Lynn L Silver; Jeffery D Hermes; Ken Bartizal; John Barrett; Dennis Schmatz; Joseph W Becker; Doris Cully; Sheo B Singh
Journal: Nature Date: 2006-05-18 Impact factor: 49.962

Review 7. Dihydrofolate reductase as a therapeutic target.

Authors: B I Schweitzer; A P Dicker; J R Bertino
Journal: FASEB J Date: 1990-05 Impact factor: 5.191

8. SQ109 targets MmpL3, a membrane transporter of trehalose monomycolate involved in mycolic acid donation to the cell wall core of Mycobacterium tuberculosis.

Authors: Kapil Tahlan; Regina Wilson; David B Kastrinsky; Kriti Arora; Vinod Nair; Elizabeth Fischer; S Whitney Barnes; John R Walker; David Alland; Clifton E Barry; Helena I Boshoff
Journal: Antimicrob Agents Chemother Date: 2012-01-17 Impact factor: 5.191

9. Discovery of platencin, a dual FabF and FabH inhibitor with in vivo antibiotic properties.

Authors: Jun Wang; Srinivas Kodali; Sang Ho Lee; Andrew Galgoci; Ronald Painter; Karen Dorso; Fred Racine; Mary Motyl; Lorraine Hernandez; Elizabeth Tinney; Steven L Colletti; Kithsiri Herath; Richard Cummings; Oscar Salazar; Ignacio González; Angela Basilio; Francisca Vicente; Olga Genilloud; Fernando Pelaez; Hiranthi Jayasuriya; Katherine Young; Doris F Cully; Sheo B Singh
Journal: Proc Natl Acad Sci U S A Date: 2007-04-24 Impact factor: 11.205

10. Morphological features and signature gene response elicited by inactivation of FtsI in Mycobacterium tuberculosis.

Authors: Richard A Slayden; John T Belisle
Journal: J Antimicrob Chemother Date: 2008-12-24 Impact factor: 5.790

7 in total

Review 1. Emerging Approaches to Tuberculosis Drug Development: At Home in the Metabolome.

Authors: Robert S Jansen; Kyu Y Rhee
Journal: Trends Pharmacol Sci Date: 2017-02-03 Impact factor: 14.819

Review 2. Targeting Phenotypically Tolerant Mycobacterium tuberculosis.

Authors: Ben Gold; Carl Nathan
Journal: Microbiol Spectr Date: 2017-01

3. Tuberculosis drug discovery in the CRISPR era.

Authors: Jeremy Rock
Journal: PLoS Pathog Date: 2019-09-19 Impact factor: 6.823

4. Two-Way Regulation of MmpL3 Expression Identifies and Validates Inhibitors of MmpL3 Function in Mycobacterium tuberculosis.

Authors: Shipra Grover; Curtis A Engelhart; Esther Pérez-Herrán; Wei Li; Katherine A Abrahams; Kadamba Papavinasasundaram; James M Bean; Christopher M Sassetti; Alfonso Mendoza-Losana; Gurdyal S Besra; Mary Jackson; Dirk Schnappinger
Journal: ACS Infect Dis Date: 2020-12-15 Impact factor: 5.084